AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently approved ...
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
AstraZeneca said its breast cancer pill camizestrant, or Etcamah, failed to significantly improve progression-free survival in the late-stage SERENA-4 trial when combined with Pfizer’s Ibrance in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — AstraZeneca said Friday ...
Sept 11 — AstraZeneca's breast cancer drug failed to meet the main goal of improving progression-free survival during a late-stage trial, it said on Friday, marking a setback for the recently ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
US-listed shares of AstraZeneca dropped about 3 per cent in aftermarket trading following the news. AstraZeneca said the full trial data will be shared in due course.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results